Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
449 studies found for:    PAH
Show Display Options
Rank Status Study
21 Completed An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Beraprost Sodium Modified Release
22 Completed Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Beraprost Sodium Modified Release
23 Active, not recruiting DelIVery for Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Device: The Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System to deliver Remodulin Injection
24 Completed A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Beraprost sodium modified release
25 Recruiting Carvedilol PAH A Pilot Study of Efficacy and Safety
Conditions: Pulmonary Hypertension;   Cardiac MRI <40
Intervention: Drug: Carvedilol
26 Recruiting National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention:
27 Completed
Has Results
Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: sildenafil citrate
28 Completed
Has Results
Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: bosentan;   Drug: placebo
29 Recruiting The Expression and Significance of MiRNA
Condition: Pulmonary Arterial Hypertension
Intervention:
30 Completed Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Sorafenib
31 Unknown  Pharmacogenomics in Pulmonary Arterial Hypertension
Conditions: Pulmonary Arterial Hypertension;   Pulmonary Hypertension;   PAH WHO Group I
Interventions: Drug: Sitaxsentan;   Drug: Bosentan, Ambrisentan
32 Completed
Has Results
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Ambrisentan;   Drug: Placebo;   Drug: Sildenafil;   Drug: Tadalafil
33 Recruiting Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Conditions: Pulmonary Arterial Hypertension;   Idiopathic Pulmonary Fibrosis
Intervention: Drug: Inhaled Nitric Oxide
34 Terminated A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: AIR001 (sodium nitrite inhalation solution)
35 Completed
Has Results
FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Hypertension
Interventions: Drug: Oral treprostinil (UT-15C) Sustained Release Tablets;   Other: Placebo
36 Recruiting A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain
Condition: Pulmonary Arterial Hypertension (PAH)
Intervention: Drug: Macitentan
37 Completed
Has Results
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Hypertension
Interventions: Drug: Oral treprostinil (UT-15C) sustained release tablets;   Drug: Placebo
38 Not yet recruiting The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Ambrisentan plus Spironolactone;   Drug: Ambrisentan plus Placebo
39 Recruiting Effects of Oral Sildenafil on Mortality in Adults With PAH
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: sildenafil citrate
40 Withdrawn Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Iloprost Inhalation Solution (Ventavis)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years